GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance

U.S. Markets close in 23 mins.

Gilead Sciences Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
70.22-0.26 (-0.37%)
As of 3:37PM EST. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close70.48
Bid70.14 x 900
Ask70.15 x 500
Day's Range70.02 - 70.99
52 Week Range65.38 - 103.10
Avg. Volume10,929,971
Market Cap91.99B
PE Ratio (TTM)7.06
Earnings DateN/A
Dividend & Yield2.08 (2.95%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com4 hours ago

    Gilead Sciences: M&A to the Rescue?

    Gilead Sciences (GILD) has been disappointing investors for nearly two years now, and many are growing impatient for the biotech giant to do something to reverse its fortunes. Part of the problem, of course, is that one of its two big businesses--hepatitis C--is curing patients, which requires very different math than chronic treatments, and no one knows how far sales will fall. In fact, Piper Jaffray's Joshua Schimmer and team are surprised it hasn't happened already: And M&A to the rescue?

  • Market Realist5 hours ago

    How Gilead’s Liver Disease Drugs Portfolio Performed

    Gilead's liver disease drugs portfolio includes drugs like Sovaldi, Viread, Harvoni, Hepsera, and Epclusa.

  • Market Realist7 hours ago

    How Gilead’s HIV Drugs Portfolio Fared in 2016

    Gilead’s (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver disease, oncology, cardiovascular, inflammation, respiratory, and others.